Marinomed focuses on growth after successful restructuring
EQS-News: Marinomed Biotech AG / Key word(s): Miscellaneous
   Marinomed focuses on growth after successful restructuring

   27.03.2025 / 07:45 CET/CEST
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

   Marinomed focuses on growth after successful restructuring

     • Marinomed plans to achieve an operating profit in 2025
     • Budesolv: innovation for the treatment of allergic rhinitis
     • Switzerland as a stepping stone for global expansion

   Korneuburg, Austria, 27. March 2025 – Marinomed Biotech AG (VSE:MARI) has
   realigned its finances after a successful restructuring and is optimistic
   about the future. After receiving a first payment of EUR 5 million,
   further financial stability should be ensured by the milestone payments
   and the ongoing transition service agreement following the sale of the
   Carragelose business to Unither Pharmaceuticals. This allows Marinomed to
   focus operationally on the Marinosolv technology, which is used to enhance
   the solubility of hydrophobic compounds. This increases their
   bioavailability and enables a faster onset of action.

   The current focus is on Budesolv, an innovative nasal corticosteroid for
   the treatment of severe allergic rhinitis (hay fever). Thanks to the
   Marinosolv technology, the required dose of commercially available active
   pharmaceutical ingredients can be reduced by around 85%, while Budesolv
   takes effect after just a few hours – in contrast to current active
   pharmaceutical ingredients, which take several days to reach full effect.
   In addition, Budesolv does not contain any harmful preservatives. The
   global market for allergic rhinitis has a volume of around USD 13 billion.

   The management has a clear strategy for marketing. In order to accelerate
   negotiations with potential pharmaceutical partners around the world,
   Budesolv shall be initially approved in a smaller market. Switzerland
   shall be the first step because the discussions and negotiations with
   potential partners and the Swiss regulatory authority Swissmedic are most
   advanced there. At the same time, the corresponding manufacturing capacity
   will be established to obtain approval in Switzerland as quickly as
   possible together with a potential partner. At the same time, discussions
   are being held regarding marketing in larger markets. In the medium term,
   the management aims to achieve a significant market share in the global
   rhinitis segment.

   A solid financial basis is the foundation for the next operational
   successes. Following the completion of the restructuring process and the
   sale of the Carragelose business, Marinomed is on the right track.
   According to preliminary calculations, the 2024 financial statements will
   close with a significant loss of around EUR 15 million due to the
   insolvency. After the legal completion of the restructuring proceedings,
   Marinomed will report a profit of around EUR 18.9 million in the first
   quarter of 2025 as a result of the restructuring alone. In addition, a
   first partial payment of EUR 5 million from the sale of the Carragelose
   business has already been received, so that the Company currently has
   sufficient liquid funds.

   “By focussing on our business, the successful restructuring and the
   associated reduction in expenses, we plan to achieve positive operating
   results from this year onwards. The aim now is to regain the confidence of
   our shareholders through operational success,” explains Andreas Grassauer,
   founder and CEO of Marinomed Biotech AG.

   About Marinomed Biotech AG

   Marinomed Biotech AG is an Austrian, science-based biotech company with a
   growing development pipeline. The Company develops innovative
   patent-protected products based on the Marinosolv® platform. The
   Marinosolv® technology improves the solubility and bioavailability of
   hardly soluble compounds and is used to develop new therapeutics for
   autoreactive immune disorders. The Company is headquartered in Korneuburg,
   Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
   further information, please visit: (1)https://www.marinomed.com.

   For further inquiries contact:

   PR: Lucia Ziegler            IR: Tobias Meister
   Marinomed Biotech AG         Meister Consulting GmbH
   T: +43 2262 90300 158        T: +43 2262 90300
   E-Mail: (2)pr@marinomed.com  E-Mail: (3)ir@marinomed.com 

   Disclaimer

   This press release contains forward-looking statements, which are based on
   current views, expectations and projections of the management of Marinomed
   Biotech AG about future events. These forward-looking statements are
   subject to risks, uncertainties and assumptions that could cause actual
   results, performance or events to differ materially from those described
   in, or expressed or implied by, such statements. The current views,
   expectations and projections of the management of Marinomed Biotech AG may
   be identified by the context of such statements or words such as
   “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
   and “target”. Forward-looking statements are only valid as of the date
   they are made and Marinomed Biotech AG does not assume any obligation to
   update, review or revise any forward-looking statements contained in this
   press release whether as a result of new information, future developments
   or otherwise. Marinomed and Marinosolv® are registered trademarks of
   Marinomed Biotech AG. These trademarks may be owned or licensed in select
   locations only.

   ══════════════════════════════════════════════════════════════════════════

   27.03.2025 CET/CEST This Corporate News was distributed by EQS Group.
   www.eqs.com

   ══════════════════════════════════════════════════════════════════════════

   Language:    English
   Company:     Marinomed Biotech AG
                Hovengasse 25
                2100 Korneuburg
                Austria
   Phone:       +43 2262 90300
   E-mail:      office@marinomed.com
   Internet:    www.marinomed.com
   ISIN:        ATMARINOMED6
   WKN:         A2N9MM
   Listed:      Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
                Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
                (Official Market)
   EQS News ID: 2106870


    
   End of News EQS News Service


   2106870  27.03.2025 CET/CEST

   https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2106870&application_name=news&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=2106870&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
   2. mailto:pr@marinomed.com
   3. mailto:ir@marinomed.com

OTS original text press release with the exclusive in terms of content of the sender – www.ots.at |

togel hari ini

demo slot x500

togel hongkong

demo slot x500

By adminn